Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
Monthly Minutes
Breast Cancer-OFS Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
Monthly Minutes
Breast Cancer-OFS Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Multimedia
All Videos
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
2018 Third Annual Oncology Guide to New FDA Approvals
Tecentriq (Atezolizumab) Receives New Indication for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Breast Cancer
,
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Yescarta (Axicabtagene Ciloleucel) Second CAR T-Cell Therapy Approved for Patients with Certain Types of Large B-Cell Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Page 2 of 2
1
2